The ASX 200 index is crashing on Monday following an equally brutal selloff on Wall Street on Friday.

While it certainly is a tough time for ASX investors, it could also be one of the best buying opportunities we have had in years and an ideal moment to snap up high-quality companies at better prices.

That's exactly what analysts at Bell Potter are suggesting. Following the selloff, the broker has been screening for "quality at a discount" — companies with strong fundamentals and long-term growth potential that have seen their valuations compress.

Two ASX 200 shares that stand out above all others for the broker are listed below. Here's what makes them so attractive right now.

ResMed Inc. (ASX: RMD)

ResMed is a global leader in medical devices and software for sleep apnoea and respiratory care. Bell Potter notes that it has a track record that would make most companies envious — delivering 12% annual earnings per share (EPS) growth since 2014, while also maintaining a ~27% net income margin and posting a return on equity (ROE) around 25%.

That sort of consistency is rare, and it's a big reason why Bell Potter considers ResMed one of its top picks. And with weight loss drugs appearing to increase awareness of sleep apnoea, this positive form could continue. It said:

Investor concerns around GLP-1 weight loss drugs weighed on the stock in 2023, but the impact has so far proved overstated. Earnings have continued to grow, and increasing GLP-1 usage appears to have raised awareness of sleep apnoea, ultimately supporting device adoption. Despite this resilience, RMD's forward P/E has derated from ~30x to ~21x, which we believe now more than reflects the risk from GLP-1s.

Telix Pharmaceuticals Ltd (ASX: TLX)

For those with a higher risk appetite, Bell Potter thinks Telix Pharmaceuticals could be an ASX 200 share to buy.

It notes that Telix has emerged as a serious player in radiopharmaceuticals, with its flagship product Illuccix already on the market. But it feels that the real excitement lies ahead. The broker highlights several major catalysts on the horizon: the upcoming launches of Gozellix and Pixclara, potential regulatory approval for Zircaix, and interim results from its ProstACT trial.

Backing that growth is a wave of acquisitions, including a deal to acquire RLS Radiopharmacies — a move that secures US distribution for its expanding pipeline. Combined, the broker believes Telix is well-placed for explosive growth in the coming years. It said:

The company has strong earnings momentum from both organic growth and these acquisitions, contributing to an attractive 44% two-year EPS CAGR, while valuations have become more reasonable (with the 12-month forward P/E now below 40x). TLX remains laser-focused on accelerating its extensive clinical pipeline to market and will continue investing aggressively through CY27 to help deliver continued strong growth across forward years.